TITLE

SUBLINGUAL HEPARIN IN HYPERLIPEMIA

AUTHOR(S)
Fuller, Harvey L.
PUB. DATE
October 1958
SOURCE
Angiology;Oct1958, Vol. 9 Issue 5, p311
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
1. Administration of heparin sublingually causes a marked clarification of postprandial lipemic serum in humans. 2. In the dosages employed, no effects were observed on the blood-clotting mechanism. 3. A practical method for the regular administration of heparin has been developed with important implications in the area of atherogenesis.
ACCESSION #
16400211

 

Related Articles

  • Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Levy, Mitchell; Levi, Marcel; Williams, Mark D.; Antonelli, Massimo; Wang, Dazhe; Mignini, Mariano Alejandro // Intensive Care Medicine;Jul2009, Vol. 35 Issue 7, p1196 

    The safety of using heparin concomitantly with drotrecogin alfa (activated) {DrotAA} was explored in the XPRESS study. No heparin effect on mortality was observed. Safety results from that study are explored in more detail. A randomized, double-blind trial of prophylactic heparin versus placebo...

  • Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Joannidis, Michael; Kountchev, Jordan; Rauchenzauner, Markus; Schusterschitz, Nicola; Ulmer, Hanno; Mayr, Andreas; Bellmann, Romuald // Intensive Care Medicine;Sep2007, Vol. 33 Issue 9, p1571 

    The purpose of this study was to evaluate the efficacy and safety of the low molecular weight heparin enoxaparin as anticoagulant in continuous veno-venous hemofiltration (CVVH) compared with unfractionated heparin. Prospective randomized controlled crossover study. Medical and Surgical...

  • Thromboembolism: unfractionated heparin revisited.  // PharmaWatch: Monthly Review;Oct2006, Vol. 5 Issue 10, p15 

    The article reports on a study that discusses the efficacy of the fixed-dose subcutaneous unfractionated heparin (UFH) to treat the acute venous thromboembolism. It is found that UFH is as effective as fixed-dose low-molecular-weight heparin (LMWH) and did not require the monitoring of blood...

  • Clot buster. Cohen, Philip // New Scientist;08/01/98, Vol. 159 Issue 2145, p6 

    Discusses the use of enoxaparin over heparin in treating the victims of heart attacks. The findings of a study of the two drugs; Enoxaparin's advantages over heparin; How each drug works.

  • Cost comparison of enoxaparin vs. unfractionated heparin. APGAR, BARBARA // American Family Physician;10/15/1998, Vol. 58 Issue 6, p1435 

    Presents the abstract of the article `Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial,' by D.B. Mark, et al. from the `Circulation' journal dated May 5, 1998.

  • Heparin. Rosenberg, Jack M.; Kirschenbaum, Harold L. // RN;Sep81, Vol. 44 Issue 9, p50 

    Offers tips on administration of heparin. Adverse effects of heparin; Safety measures for administering intravenous heparin with infusion pumps; Signs of hemorrhage due to heparin.

  • Apixaban.  // AHFS Consumer Medication Information;Apr2017, p1 

    Apixaban is used help prevent strokes or blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes) that is not caused by heart valve disease. Apixaban is in a class of...

  • Apixaban.  // AHFS Consumer Medication Information;Apr2017, p1 

    Apixaban is used help prevent strokes or blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes) that is not caused by heart valve disease. Apixaban is in a class of...

  • Pitfalls in patient self-management of subcutaneous drug application: removal of rubber protection caps from ready-to-use syringes. Mengiardi, Seraina; Goepfert, Beat; Tsakiris, Dimitrios A.; Hersberger, Kurt E. // European Journal of Clinical Pharmacology;Oct2009, Vol. 65 Issue 10, p1061 

    The article discusses the issues with outpatient subcutaneous therapies, which are reportedly becoming more common, such as the use of low-molecular-weight heparins (LMWH). Being cited are some of the methodological approaches used including the self-assessment through population study,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics